BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Guedan S, Gros A, Cascallo M, Vile R, Mercade E, Alemany R. Syncytia formation affects the yield and cytotoxicity of an adenovirus expressing a fusogenic glycoprotein at a late stage of replication. Gene Ther 2008;15:1240-5. [PMID: 18509378 DOI: 10.1038/gt.2008.94] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Burton C, Bartee E. Syncytia Formation in Oncolytic Virotherapy. Mol Ther Oncolytics 2019;15:131-9. [PMID: 31890866 DOI: 10.1016/j.omto.2019.09.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
2 Gros A, Puig C, Guedan S, Rojas JJ, Alemany R, Cascallo M. Verapamil enhances the antitumoral efficacy of oncolytic adenoviruses. Mol Ther 2010;18:903-11. [PMID: 20179683 DOI: 10.1038/mt.2010.22] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
3 Martinez-Quintanilla J, Seah I, Chua M, Shah K. Oncolytic viruses: overcoming translational challenges. J Clin Invest 2019;129:1407-18. [PMID: 30829653 DOI: 10.1172/JCI122287] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 10.7] [Reference Citation Analysis]
4 Rojas JJ, Cascallo M, Guedan S, Gros A, Martinez-quintanilla J, Hemminki A, Alemany R. A modified E2F-1 promoter improves the efficacy to toxicity ratio of oncolytic adenoviruses. Gene Ther 2009;16:1441-51. [DOI: 10.1038/gt.2009.103] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
5 Rojas JJ, Guedan S, Searle PF, Martinez-Quintanilla J, Gil-Hoyos R, Alcayaga-Miranda F, Cascallo M, Alemany R. Minimal RB-responsive E1A promoter modification to attain potency, selectivity, and transgene-arming capacity in oncolytic adenoviruses. Mol Ther 2010;18:1960-71. [PMID: 20808288 DOI: 10.1038/mt.2010.173] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 3.9] [Reference Citation Analysis]
6 Guedan S, Grases D, Rojas JJ, Gros A, Vilardell F, Vile R, Mercade E, Cascallo M, Alemany R. GALV expression enhances the therapeutic efficacy of an oncolytic adenovirus by inducing cell fusion and enhancing virus distribution. Gene Ther 2012;19:1048-57. [PMID: 22113313 DOI: 10.1038/gt.2011.184] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
7 Clarkin RG, Del Papa J, Poulin KL, Parks RJ. The genome position of a therapeutic transgene strongly influences the level of expression in an armed oncolytic human adenovirus vector. Virology 2021;561:87-97. [PMID: 34171766 DOI: 10.1016/j.virol.2021.06.005] [Reference Citation Analysis]
8 Durupt F, Koppers-lalic D, Balme B, Budel L, Terrier O, Lina B, Thomas L, Hoeben RC, Rosa-calatrava M. The chicken chorioallantoic membrane tumor assay as model for qualitative testing of oncolytic adenoviruses. Cancer Gene Ther 2012;19:58-68. [DOI: 10.1038/cgt.2011.68] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 2.7] [Reference Citation Analysis]
9 Coughlan L, Vallath S, Gros A, Giménez-alejandre M, Van Rooijen N, Thomas GJ, Baker AH, Cascalló M, Alemany R, Hart IR. Combined Fiber Modifications Both to Target α v β 6 and Detarget the Coxsackievirus–Adenovirus Receptor Improve Virus Toxicity Profiles In Vivo but Fail to Improve Antitumoral Efficacy Relative to Adenovirus Serotype 5. Human Gene Therapy 2012;23:960-79. [DOI: 10.1089/hum.2011.218] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
10 Mantwill K, Klein FG, Wang D, Hindupur SV, Ehrenfeld M, Holm PS, Nawroth R. Concepts in Oncolytic Adenovirus Therapy. Int J Mol Sci 2021;22:10522. [PMID: 34638863 DOI: 10.3390/ijms221910522] [Reference Citation Analysis]
11 Del Papa J, Parks RJ. Adenoviral Vectors Armed with Cell Fusion-Inducing Proteins as Anti-Cancer Agents. Viruses 2017;9:E13. [PMID: 28106842 DOI: 10.3390/v9010013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
12 Chen HH, Cawood R, El-Sherbini Y, Purdie L, Bazan-Peregrino M, Seymour LW, Carlisle RC. Active adenoviral vascular penetration by targeted formation of heterocellular endothelial-epithelial syncytia. Mol Ther 2011;19:67-75. [PMID: 20877345 DOI: 10.1038/mt.2010.209] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
13 van Zeeburg HJ, Huizenga A, Brink A, van den Doel PB, Zhu ZB, McCormick F, Brakenhoff RH, van Beusechem VW. Comparison of oncolytic adenoviruses for selective eradication of oral cancer and pre-cancerous lesions. Gene Ther 2010;17:1517-24. [PMID: 20686507 DOI: 10.1038/gt.2010.99] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
14 Del Papa J, Petryk J, Bell JC, Parks RJ. An Oncolytic Adenovirus Vector Expressing p14 FAST Protein Induces Widespread Syncytium Formation and Reduces Tumor Growth Rate In Vivo. Mol Ther Oncolytics 2019;14:107-20. [PMID: 31193718 DOI: 10.1016/j.omto.2019.05.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
15 Del Papa J, Clarkin RG, Parks RJ. Use of cell fusion proteins to enhance adenoviral vector efficacy as an anti-cancer therapeutic. Cancer Gene Ther 2021;28:745-56. [DOI: 10.1038/s41417-020-0192-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Krabbe T, Altomonte J. Fusogenic Viruses in Oncolytic Immunotherapy. Cancers (Basel) 2018;10:E216. [PMID: 29949934 DOI: 10.3390/cancers10070216] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]